VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING CHEMOTHERAPY: PREDICTORS AND PREVENTION

Abstract

Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a prevalent and life-threatening complication among cancer patients receiving chemotherapy. This study investigates the predictive factors and preventive strategies associated with VTE occurrence in oncology settings. Utilizing a mixed-methods approach, quantitative data was collected from simulated clinical datasets across diverse cancer types and treatment modalities, while qualitative insights were integrated to capture contextual patient care variables. Advanced statistical analysis and visualization techniques were employed to identify critical risk factors including elevated D-dimer levels, high platelet counts, specific tumor sites, and regimen-specific toxicities. The study also assessed the effectiveness of various thromboprophylaxis interventions and their correlation with patient outcomes. Through a series of multivariate models and data-driven simulations, we observed that early screening, tailored anticoagulant use, and dynamic risk stratification significantly reduced VTE incidence. The comprehensive tables and figures included in the results highlight notable trends, such as time-to-VTE onset, coagulopathy profiles, and treatment-specific risk burdens. This study reinforces the importance of integrating genetic, physiological, and clinical risk factors into routine oncology workflows and advocates for a proactive, individualized approach to VTE prevention. The findings serve as a practical guide for clinicians to optimize chemotherapy protocols while minimizing thrombotic complications, thereby improving patient safety and long-term prognosis in cancer therapy.